03:09 PM EDT, 07/26/2024 (MT Newswires) -- The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's ( NVO ) weight loss drug semaglutide.

The agency said it had received reports of adverse events, some requiring hospitalization, caused by patients measuring and self-administering incorrect doses of the drug and healthcare providers miscalculating doses of the medicine.

The FDA said there was "unfamiliarity" and "confusion" on how to withdraw and measure the medication from a vial. It also said that many of the patients using semaglutide "lacked experience" with self-injections which may have resulted in overdosage.

Overdosage of semaglutide can result in severe nausea, severe vomiting, and low blood sugar levels, according to the drug's prescribing information.

Novo Nordisk ( NVO ) did not immediately respond to a request for comment from MT Newswires.

Price: 127.05, Change: -0.81, Percent Change: -0.63